Commentary Open Access
Volume 3 | Issue 2 | DOI: https://doi.org/10.33696/Nanotechnol.3.033
A Short Commentary of Nanotechnology on Traditional Chinese Medicine
Siukan Law1,*, Dawn Chingtung Au1, Albert Wingnang Leung2, Chuanshan Xu3
- 1Faculty of Science and Technology, The Technological and Higher Education Institute of Hong Kong, Tsing Yi, New Territories, Hong Kong
- 2School of Nursing, Tung Wah College, 31 Wylie Road, Ho Man Tin, Kowloon, Hong Kong
- 3Key Laboratory of Molecular Target and Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China
Corresponding Author
Siukan Law, siukanlaw@hotmail.com, siukanlaw@vtc.edu.hk
Received Date: May 02, 2022
Accepted Date: May 23, 2022
Law S, Au DC, Leung AW, Xu C. A Short Commentary of Nanotechnology on Traditional Chinese Medicine. J Nanotechnol Nanomaterials. 2022;3(2):77-78.
Copyright: © 2022 Law S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Traditional Chinese medicines (TCM) have many bioactive ingredients or parts, but there are still some limitations for medical field application, such as solubility and absorptivity in the human body. Nanotechnology is an effective way to enhance its bioavailability. How do we incorporate traditional Chinese medicines (TCM) with nanotechnology? This short commentary discusses the background of nanotechnology and its research progress with TCM as well as the future aspects.
Recommended Articles
In silico Analysis for the Repurposing of Broad-spectrum Antiviral Drugs against Multiple Targets from SARS-CoV-2: A Molecular Docking and ADMET Approach
SARS-CoV-2 belongs to the genus Beta of the Coronaviridae family of enveloped single-stranded, positive-sense ribonucleic acid (RNA) with a genome length of 30,000bp. The virion is composed of various non-structural (RNA dependent RNA polymerase also known as RdRp) and structural proteins such as Spike (S), Nucleocapsid (N), Matrix (M), and Envelope (E) proteins.
Dexamethasone: The First Drug to be Shown to Decrease Mortality in Critically Ill Patients with COVID-19
The precise role of corticosteroids for treatment of coronavirus disease 2019 (COVID-19) is unclear due to lack of randomized trials.
How to Prevent Rehospitalization in Patients with COVID-19
Since December 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) caused by 2019 Novel Coronavirus (2019-nCoV) has resulted in 89,000 cases of Corona Virus Disease 2019 (COVID-19), formerly known as Novel Coronavirus Pneumonia (NCP) in China, including 2,450 deaths.
Beta-Sitosterol: As Immunostimulant, Antioxidant and Inhibitor of SARS-CoV-2 Spike Glycoprotein
This article is an extension to our recently published article in Asian Journal of Pharmaceutical and Clinical Research, entitled “Β-Sitosterol: Isolation from Muntingia Calabura Linn. Bark Extract, Structural Elucidation, and Molecular Docking Studies as Potential Inhibitor of SARSCoV-2 Mpro (COVID-19)”[1].
Rapid Inactivation of SARS-CoV-2 by Coupling Tungsten Trioxide (WO3) Photocatalyst with Copper Nanoclusters
At the end of 2019, a novel severe respiratory disease (coronavirus disease 2019, COVID-19) spread to Wuhan, China, it became pandemic in few months, with more than 41 million people infected worldwide as of October 2020. COVID-19 is caused by a novel virus called severe acute respiratory syndrome (SARS) CoV-2 to distinguish it from SARS-CoV that emerged in Guangdong province in China in 2003 and caused the severe clinical condition known as SARS. Like SARS-CoV, SARS- CoV-2 causes a severe inter